Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect

The combination of MEK inhibitor (cobimetinib, trametinib) and BRAF inhibitor (vemurafenib, dabrafenib) is now the first-line treatment in patients with BRAF V600-mutated metastatic melanoma. This association reduces cutaneous adverse events induced by BRAF inhibitors alone, including photosensitivi...

Full description

Bibliographic Details
Main Authors: Miruna Negulescu, Florian Deilhes, Vincent Sibaud, Emilie Tournier, Laurence Lamant, Serge Boulinguez, Nicolas Meyer
Format: Article
Language:English
Published: Karger Publishers 2017-03-01
Series:Case Reports in Dermatology
Subjects:
BRAF V600E melanoma
Panniculitis
MEK inhibitors
Cobimetinib
Trametinib
Online Access:http://www.karger.com/Article/FullText/461571

Internet

http://www.karger.com/Article/FullText/461571

Similar Items